ABSTRACT: Neutralizing monoclonal sclerostin antibodies are effective in promoting bone formation at a systemic level and in orthopedic scenarios including closed fracture repair. In this study we examined the effects of sclerostin antibody (Scl-Ab) treatment on regenerate volume, density, and strength in a rat model of distraction osteogenesis. Surgical osteotomy was performed on 179 Sprague Dawley rats. After 1 week, rats underwent distraction for 2 weeks, followed by 6 weeks for consolidation. Two treatment groups received biweekly subcutaneous Scl-AbIII (a rodent form of Scl-Ab; 25 mg/kg), either from the start of distraction onward or restricted to the consolidation phase. These groups were compared to controls receiving saline. Measurement modalities included longitudinal DXA, ex vivo QCT, and microCT, tissue histology, and biomechanical four-point bending tests. Bone volume was increased in both Scl-Ab treatments regimens by the end of consolidation (þ26-38%, p < 0.05), as assessed by microCT. This was associated with increased mineral apposition. Importantly, Scl-Ab led to increased strength in united bones, and this reached statistical significance in animals receiving Scl-Ab during consolidation only (þ177%, p < 0.01, maximum load to failure). These data demonstrate that Scl-Ab treatment increases bone formation, leading to regenerates with higher bone volume and improved strength. Our data also suggest that the optimal effects of Scl-Ab treatment are achieved in the latter stages of distraction osteogenesis. These findings support further investigation into the potential clinical application of sclerostin antibody to augment bone distraction, such as limb lengthening, particularly in the prevention of refracture. ß
Distraction osteogenesis (DO) is a widely used technique in orthopedics, plastic surgery reconstructions, and the treatment of dentofacial deformities and defects. 1 DO harnesses a potent endogenous anabolic response to the gradual separation of bone ends at an osteotomy site. The resulting regenerate bridges the distracted site before being remodeled into mature cortical bone. Although this is a well-established surgical technique, complications are still common. In many cases an underlying bone pathology in patients can yield an insufficient regenerative response resulting in poor new bone formation, hypertrophic nonunion, 2 and/or localized disuse osteopenia. 3 To overcome some of the challenges associated with DO, several adjunctive therapeutic responses have been explored in preclinical models. The bisphosphonates, a class of bone-binding anti-resorptive drugs, are able to potently reduce bone turnover and maintain bone mass. In the context of DO, bisphosphonate co-treatment has been shown to prevent premature or excessive resorption of the regenerate and produced superior outcomes in rabbit DO models. 4, 5 Other alternative strategies include promoting angiogenesis, such as with VEGF, 6 or platelet rich plasma, 7 or by utilizing agents that increase bone formation (BMP-2, 8 BMP-7, 9, 10 or PTH (1-34) 11 ). Growth factor-modified bone marrow cells have also shown potential to improve the healing response in animal models. 9, 12 However, few of these approaches have been applied clinically. Positive outcomes were cited in a case series where DO patients received systemic treatment with the bisphosphonate zoledronic acid. 13 Local BMP-7 (OP-1) 14 has also been successfully used in pediatric limb lengthening as an anabolic driver, despite preclinical data that intimated challenges associated with the OP-1 implant carrier. 10 Alternatively, local application of autogenous platelet rich plasma has been shown to significantly shorten treatment time in a retrospective patient study. 15 Despite these documented clinical cases, tools to robustly increase bone formation during distraction osteogenesis in the clinic are lacking.
The Wnt/b-catenin pathway has emerged as a key axis for modulating bone mass. Loss or antagonism of the Wnt/b-catenin regulator sclerostin results in increased bone formation and high bone mass. Neutralizing antibodies to sclerostin (Scl-Ab) were shown to stimulate bone anabolism in preclinical studies of post-menopausal osteoporosis. 16, 17 More recently, in phase II and III clinical trials, sclerostin antibodies produced increases in bone mass and estimated strength in the femoral neck of osteoporotic women. [18] [19] [20] In a rat OVX tibial defect model, Scl Ab treatment enhanced defect repair 21 and in a rat closed fracture model, sclerostin antibody was found to augment bony callus size and strength. 22 Consequently, we hypothesized that Scl-Ab treatment will increase density and strength of the regenerate in a DO setting.
We undertook a study in rats where a femoral osteotomy was distracted over 2 weeks, allowing up to 6 weeks for consolidation. Scl-AbIII, a rodent form of Scl-Ab, was dosed using two regimens: One from the commencement of distraction (continuous) and one where dosing was limited to the consolidation phase only (delayed). Key outcome measures included regenerate bone formation and density, and biomechanical strength.
MATERIALS AND METHODS

Osteotomy Surgery and Distraction
The study was approved under South Western Area Health Service (SWAHS) ethics protocol 4139. Fourteen week old male Sprague Dawley rats (N ¼ 179) were purchased from the Animal Resources Centre (ARC, Australia). Animals were housed 4/cage and kept in a 12-h light/dark cycle, with food and water ad libitum. Animals were monitored daily for signs of distress or pain. Weekly weight changes from date of surgery are shown in Figure S1 . Animals received one week acclimatization prior to operation.
Osteotomy surgery was performed at 15 weeks of age under complete anesthesia, at week À1 (35 mg/kg ketamine, 4 mg/kg xylazine). In brief, an incision was made from the lateral aspect of the hip joint to the lateral side of the knee joint, and the skin and surrounding muscle reflected to expose the femur. An EBI Pennig mini-fixator (Orthofix, Lewisville, TX) was then placed on the area to determine the sites for the holes to be drilled. A drill guide was used to place a 0.9 mm hole distally into the femur and a 1.4 mm screw was placed using the guide to ensure that it was 90˚to the bone. The proximal pin was then placed using a guide to ensure that it was parallel to, and in the same plane as, the first screws and 25 mm apart. The fixator was then applied loosely and a guide used for the two central screws. Once applied, an osteotomy was made between the central screws and the site was washed with sterile saline. The incision was then closed in two layers with 4/0 Vicryl, and the animals allowed to recover under monitoring and receiving pain relief (0.05 mg/kg buprenorphine). The baseline distance between proximal and distal fixator plates was measured using calipers.
A timeline for the study design is detailed in Figure 1 . A 1 week latency was allowed following osteotomy surgery before distraction commenced at week 0. A standard distraction rate of 0.25 mm twice daily was used to lengthen 7 mm over 2 weeks, until week 2. Following distraction, the regenerate was allowed to consolidate up to 6 weeks, with specimens collected at two weekly intervals. These endpoints were at week 4, 6, and 8 weeks following the commencement of distraction.
A total of N ¼ 34 rats were excluded from all subsequent analysis. These include N ¼ 12 that died or were euthanized during surgery due to complications from anesthetics or fracture or unacceptable displacement of the femora; N ¼ 6 that died from unknown respiratory problems subsequent to surgery; N ¼ 14 that were culled prior to the experimental endpoint due to unexpected fragmentation of the femoral cortex or evidence of osteolytic bone infection; and N ¼ 2 specimens that were accidently damaged during pin removal post-harvest. Supplementary Table S1 contains the number of animals excluded from the study, specifying the number excluded prior to drug treatment commencement, and the number of rats within each drug treatment group if excluded once drug treatment had commenced. Drug treatment did not influence the rate of exclusion as measured by Fisher's exact and chi-square testing.
Post-Operative Dosing and Specimen Collection
Scl-AbIII, a rodent form of Scl-Ab, was provided by Amgen Inc. (Thousand Oaks, CA) and UCB (Brussels, Belgium). Control animals received subcutaneous (s.c.) twice weekly saline from week 0 (the start of distraction) until sacrifice ( Fig. 1) . The C.Scl-Ab group received Scl-AbIII s.c. 25 mg/kg twice weekly starting at week 0, from the commencement of distraction, and continuing until animal sacrifice. The D.Scl-Ab group received Scl-AbIII s.c. 25 mg/kg twice weekly commencing at week 2, after the distraction had ceased and the commencement of the consolidation period, until sacrifice. Animals were randomized into treatment groups and dosing of the rats was performed near the home cage of the rat. All rats received 10 mg/kg s.c. calcein 10 and 3 days prior to sacrifice.
After sacrifice, the distracted and contralateral femora were dissected free of soft tissue and underwent radiographic scanning. Specimens for mechanical testing were wrapped in saline-soaked gauze and frozen (unfixed) at À80˚C. Specimens for histology were fixed for 24 h in 4% paraformaldehyde, and stored in 70% ethanol prior to histological processing.
Radiographic Assessment and Union Grading
All rats underwent longitudinal (weekly) dual-energy absorptiometry (DXA) scanning using a PIXImus small-animal A region of interest of 22 Â 34 pixels was analyzed centered within the bone regenerate. Bone mineral density (BMD), bone mineral content (BMC), and bone volume (BV) were obtained from these analyses.
Dissected femora were imaged by quantitative computed tomography (QCT) using an XCT Research SA scanner (Stratec Medizintechnik GmbH, Pforzheim, Germany) and by microCT using a Skyscan 1174 scanner (Skyscan NV, Kontich, Belgium). For QCT, 7 slices 1 mm apart were measured centered within the regenerate of the fractured femora. Bone mineral density (BMD), bone mineral content (BMC), and bone volume (BV) were determined for each regenerate and intact bone.
For microCT, femora were scanned at an isotropic voxel resolution of 14 mm with a 0.5 mm aluminum filter, 50 kV X-ray tube voltage, 800 mA tube electric current, and 4,500 ms scanning exposure time. Images were reconstructed for analysis using a scale of 0-0.07 (NRecon version 1.6.1.7; Skyscan NV). All analysis was performed using CTAnalyser (Skyscan NV). BV was assessed in the regenerate using a volume of interest in cross-sections bound by the old cortical bone.
Maximum intensity projections of the distracted femora were generated from microCT scans using CTAnalyser. Union (bridging) at 8 weeks was assessed from these images by a blinded observer. Cut-off values for union and nonunions were empirically chosen based on advice from clinical colleagues. Non-unions showed >10% of the regenerate at distal and proximal ends was bridged to the original cortex. Unions showed >80% of the regenerated bridged to the original cortex. Values between 10% and 80% were graded as partial unions. DXA, QCT, microCT, histomorphometry, and mechanical testing outcomes were performed on partial unions and unions.
Histomorphometry
Femora for histomorphometry were processed to methyl methacrylate resin and 5 mm sections cut through the center of the specimen in the coronal plane. Von Kossa staining allowed analysis of bone volume fraction (BV/TV, %) at weeks 4, 6, and 8. Unstained sections were assessed for mineral apposition rate (MAR, mm) at weeks 6 and 8. Due to the irregular nature of the regenerate bone, mineralizing surface, and bone formation rate (BFR) could not be measured reliably. Analysis was performed on an ROI bound by the original cortices of the long bone on the longitudinal axis, using BIOQUANT measure 32 Nova Prime software (Nashville, TN), captured using the QICAM Fast 1394 color 12 bit camera (QImaging, BC, Canada). The assessor was blinded to treatment group. Representative images were captured by Scanscope CS2 and Aperio Imagescope v11.2.0.780 (Aperio, Vista, CA).
Biomechanical Testing
Distracted and contralateral intact femora underwent four-point bending to failure using Instron 5944 (Instron, Mechanical Testing Jig, Norwood, MA) by an assessor blinded to treatment group. Data were collected using BlueHill 3 software (Instron). Femora were stored at À80˚C, and prior to testing were allowed to thaw to room temperature and cleaned of soft tissue. Femora were positioned for testing so that the posterior surface rested on the bottom span, with the upper fixture resting on the mid diaphysis. The support span was 27 mm, with the upper span measure 9 mm. Samples were pre-loaded at 0.5 mm/min until a load of 5 N was reached, at which point the loading rate increased to 2 mm/min until fracture. Maximum load to failure data were collected for each specimen, and the mean calculated per group. Stiffness (N/mm) was approximated from the slope of the elastic portion of the load-displacement curve using a regression line fit. Energy until maximum load (J) was calculated from the area under the curve until maximum load. BMC, obtained from QCT analysis, was compared to maximum load to failure for each specimen.
Statistical Analysis
Fisher's exact and chi-square testing were used to assess union grading and exclusion rates. Parametric one-way ANOVA was used to assess whole animal DXA data. As bone formation associated with distraction is not known to follow a normal distribution, analysis of regenerate by QCT, microCT, histomorphometry, and mechanical testing were performed using non-parametric independent sample testing using Kruskal-Wallis and post hoc Mann-Whitney-U. Linear regression of BMC from microCT versus maximum load to failure from mechanical testing was performed.
All statistical tests were performed using IBM SPSS 20 (SPSS Inc., Chicago, IL). A p-value cutoff of p < 0.05 was used to determine significance. Error bars represent the standard deviation.
RESULTS
Sclerostin Antibody Treatment Increases the Size and Density of the DO Regenerate Without Altering the Union Rate
Union rate was determined by blinded grading at the end point of 8 weeks. Both C.Scl-Ab and D.Scl-Ab regimens (continuous and delayed) did not significantly change the union rate compared to controls ( Table 1) .
The bone volume, density, and mineral content of the regenerate region were longitudinally measured by DXA on weeks 4, 6, and 8 during the consolidation phase (Fig. 2) . Saline controls showed steady increases in BV, BMD, and BMC in the regenerate over time. Compared to saline controls, the C.Scl-Ab group (dosed during distraction and consolidation) showed significantly increased BV, BMD, and BMC at 8 weeks. The D.Scl-Ab group showed a similar anabolic bone response, however these increases were not significant by 8 weeks.
Volumetric assessment of the regenerate was examined at 8 weeks via QCT (Fig. 3A) . This testing Percent of all samples graded as non-union, partial union or union. A non-union has less than 10% of the regenerate at distal and proximal ends bridging the original cortex. A partial union has 10-80% of the regenerate at distal and proximal ends bridging the original cortex. A union has more than 80% of the regenerate at distal and proximal ends bridging the original cortex.
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modality affirmed significant increases in BMD (þ7%, p < 0.01) and BMC (þ33%, p < 0.05) with C.Scl-Ab treatment compared to saline by the 8 week end-point (Fig. 3A) . BV was also shown to be increased by 8 weeks with C.Scl-Ab treatment compared to saline when assessed by QCT (þ25%, p < 0.05; Fig. 3A ) This was confirmed by microCT (BV þ38%, p < 0.01; Fig. 3B ) and these increases are represented by 3D (Fig. 3C) . The regenerate from the D.Scl-Ab treatment group also had a significant increase in BV compared to the saline regenerate as assessed by microCT (þ26%, p < 0.05). These data were modeled in 3D using reconstruction software (Fig. 3C ) Histological assessment of Von Kossa stained mineralized sections likewise indicated that the regenerates in the Scl-Ab treated specimens were larger and denser (Fig. 4) . This was illustrated by a greater areal BV/TV, significant for the C.Scl-Ab group at week 8 (þ42%, p < 0.05).
Sclerostin Antibody Treatment Increases Mineral Apposition in the Regenerate Region
Dynamic histomorphometry analysis of mineral apposition within the entire regenerate for each specimen revealed increased bone formation responses with Scl-Ab treatment (Fig. 5) . Significantly increased MAR was seen in both Scl-Ab treated groups. The C.Scl-Ab group showed þ89% (week 6) and þ73% (week 8) above saline (p < 0.01). The D.Scl-Ab group showed þ72% (week 6) and þ80% (week 8) above saline (p < 0.01). These data indicate a considerable increase in bone anabolism with Scl-Ab treatment.
Sclerostin Antibody Treatment Increases Biomechanical Strength in the Distracted Limb
Biomechanical strength was tested by four-point bending on united and partially united specimens at the end of the 6 week consolidation phase (week 8; Fig. 6A ). Maximum load to failure was increased by þ177% in the D.Scl-Ab group compared to saline controls (p < 0.01). The C.Scl-Ab group had an even larger (þ194%) increase in maximum load to failure compared to saline, however this did not reach 
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significant due to the higher variance in this group (p ¼ 0.07). Stiffness was 269% greater in the C.Scl-Ab group and 302% greater in the D.Scl-Ab group compared to saline (p < 0.05). Energy to maximum load was not significantly increased by Scl-Ab. The contralateral intact femora were also tested by four-point bending to investigate the systemic effects that Scl-Ab treatment had on bone strength (Fig. 6B) . The strength of the intact femora was increased with continuous Scl-Ab treatment, with both maximum load to failure and stiffness significantly increased within the C.Scl-Ab group compared to saline (þ49% and þ63%, respectively, p < 0.01). The D.Scl-Ab also showed increased strength compared to saline (maximum load to failure þ27% and stiffness þ29%, p < 0.05), but did not achieve that of the C.Scl-Ab group.
By the experimental endpoint (after 6 weeks of consolidation), in all groups the strength of the distracted femora did not yet reach a comparable strength to their intact contralateral femora. Notably, the Scl-Ab treated distracted femora also did not reach the strength of saline contralateral intact femora.
Mechanical testing outcomes were also analyzed for the entire dataset; that is including all union, partial union, and non-union specimens. This data is shown in Figure S2 . Results did not differ to the data of union and partial union specimens only, however the increased maximum load to failure seen within the C.Scl-Ab distracted femora reached significance when the non-unions were included in the analysis (p < 0.05).
DISCUSSION
In this study, we examined sclerostin antibody regimens in a preclinical rat DO model featuring a 2 week distraction phase and a 6 week consolidation phase. Notably, sclerostin antibody treatment led to a considerable and statistically significant increase in density of the regenerate. This was associated with increased 
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regenerate volume, mineral apposition rate in the regenerate, and importantly led to increased mechanical strength in the D.Scl-Ab group. Bone generated during the process of distraction osteogenesis appears to involve a mix of endochondral, intramembranous, and "transchondroid" processes. 23 Thus these data suggest that treatment with Scl-Ab can affect bone volume by influencing one or more of these processes.
In this DO model, the rates of non-union after 6 weeks of consolidation were comparable between all treatment and control groups ($23-26%). Thus while Scl-Ab led to denser, stronger regenerates, it did not result in improved union. These data indicate that the treatment may only augment anabolism within a developing regenerate, rather than rescue an atrophic non-union. Similar findings were reported with sclerostin antibody treatment in a rat osteotomy model without distraction, where nonunion was seen in 5/30 sclerostin antibody treated animals and 1/30 control animals. 24 Despite this, fracture callus BV/TV as measured by microCT was increased with Scl-Ab treatment, supporting the outcomes of our study.
One key feature of our study design was to compare dosing during distraction and consolidation versus dosing during consolidation alone. We had hypothesized that as sclerostin antibody chiefly functions to augment density of an existing regenerate, that restricting treatment to consolidation only may be sufficient to obtain similar benefits. Anabolic bone responses were seen with both sclerostin antibody treatment regimens with comparable increases in bone formation parameters, however it was the longer dosing regimen that achieved maximal statistical benefit in regenerate volume and density. A limitation of this study was that bone resorption was not specifically analyzed and the anti-resorptive effects of Scl-Ab are being increasingly appreciated. 25 During distraction osteogenesis, osteoclastic forces become more important during consolidation, and thus Scl-Ab treatment spanning both distraction and consolidation may be superior to during distraction alone.
Importantly though, the mechanical strength increases over control were similar for both sclerostin antibody dosing regimens, however this was statistically significant only for the group treated within the consolidation phase (D.Scl-Ab). This was likely a result of greater variance in the data of the C.Scl-Ab group and associated with a higher number of partial unions in the C.Scl-Ab group. An alternative interpretation is that the consolidation phase is the critical stage for intervention with sclerostin antibody. Expression of native sclerostin may be greatest during the latter stages of regenerate formation, such that the neutralizing antibody is most effective at this time. Sclerostin is chiefly expressed by osteocytes, which have been shown to be present in regenerating bone as early as day 5 in a murine fracture model, but increase over time. 26 Our data are supported by previous findings in a murine tibial DO model. 27 Makhdom et al. used sclerostin antibody from an alternative source (Novartis AG, Switzerland) and a modified but comparable distraction timing to our study. Sclerostin antibody dosing was initiated at the time of surgery and maintained throughout the duration of the study. These authors demonstrated significantly increased regenerate density with sclerostin antibody, and also increases in biomechanical strength that however did not reach statistical significance. In contrast, maximal load to failure was significantly increased in the D.Scl-Ab group in the current study. This may be due to increased sample size in our study as well as the decreased variance typically seen in rat bones compared to mouse bones.
In a clinical setting, refracture of a distracted bone due to insufficient density and strength of the regenerate can be expensive and challenging to manage. A recent systematic review of DO indicated a refracture rate of 5%, with a significantly higher odds ratio in the tibia. 28 Our preclinical data suggest that sclerostin antibody treatment can increase regenerate size and density and improve regenerate strength, providing evidence for conducting clinical trials in patients at high-risk of refracture. This supports further development and assessment of sclerostin antibody treatment as an adjunctive treatment for DO in the clinical setting, particularly for the potential prevention of refracture. Future studies would need to be designed to provide a faster distraction rate, or test consolidation strength at earlier time points to specifically address these issues.
